Abstract: . . .  they display different perceptions of risk. For the “supporter”, risk is not an issue. The “risk tolerant supporter” perceives risk but then discounts it. Opponents take a position exactly opposite to that of supporters. Table 4 shows the logics of support for each of the 6 applications used in 2002, and time series comparisons with the 1996 and/or 1999 Eurobarometers where there is available data. It is important to bear in mind that the figures in the three columns are based on only those respondents who held one of the three common logics. As such column 1, 1996, is based on 58%of the sample. Column 2, for 1999 is based on 49% and column 3, for 2002 reflects 45% of the sample. The decline in the percentage . . .
. . .  has a similar trajectory to GM crops. Between 1996 and 1999 both categories of support declined and opposition increased. Post 1999 there is again virtually no change. Amongst the decided public in 2002, overall support and opposition for GM foods is equally divided. The time Page 20 -------------------------------- Europeans and Biotechnology in 2002 (2 nd Edition: 21/03/03) ----------------------------- 17 series data for cloning human cells and tissues covers 1999 and 2002. Support for this application is unchanged, with an aggregate level of 82%. For xenotransplantation, the two availa . . .
. . .  decided public in 2002, overall support and opposition for GM foods is equally divided. The time Page 20 -------------------------------- Europeans and Biotechnology in 2002 (2 nd Edition: 21/03/03) ----------------------------- 17 series data for cloning human cells and tissues covers 1999 and 2002. Support for this application is unchanged, with an aggregate level of 82%. For xenotransplantation, the two availa . . .
. . .  trajectory to GM crops. Between 1996 and 1999 both categories of support declined and opposition increased. Post 1999 there is again virtually no change. Amongst the decided public in 2002, overall support and opposition for GM foods is equally divided. The time Page 20 -------------------------------- Europeans and Biotechnology in 2002 (2 nd Edition: 21/03/03) ----------------------------- 17 series data for cloning human cells and tissues covers 1999 and 2002. Support for this application is unchanged, with an aggregate level of 82%. For xenotransplantation, the two availa . . .
--3000,4,375,2946,64634